Enzastaurin HCl

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Colonic NeoplasmsNon-Small-Cell Lung Carcinoma

Phase 2

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

CompletedNCT00105092

Eli Lilly and CompanyNon-Small-Cell Lung Carcinoma

Start: 2005-03-31End: 2007-02-28Target: 50Updated: 2007-05-01

Enzastaurin for Patients With Metastatic Colorectal Cancer

CompletedNCT00192114

Eli Lilly and CompanyColonic Neoplasms

Start: 2005-08-31End: 2008-03-31Updated: 2020-08-06